FDA issues draft guidance on 503B wholesaling
This week, FDA published a new draft guidance on the Prohibition on Wholesaling Under Section 503B of the Federal Food, Drug, and Cosmetic Act.
This week, FDA published a new draft guidance on the Prohibition on Wholesaling Under Section 503B of the Federal Food, Drug, and Cosmetic Act.
This week the APC Board of Directors selected locations for the 2026 and 2027 Owner Summits.
You need to urge them to add their names to a letter to FDA led by Senators Baldwin (WI) and Marshall (KS) urging the agency to base any action on compounded hormones on legitimate science...
Compounders on Capitol Hill, APC’s annual DC fly-in, is September 19-20—just under three months away. But what’s NOT three months away is our early bird registration deadline, coming up July 7.
Here's another exclusive benefit for our PFMs...
Twenty-five members of Congress signed a joint letter that was sent this week to FDA urging that the agency protect compounded hormone therapy.
Nevada SB 161 has been signed into law by the governor and contains provisions that affect 503B outsourcing facilities...
This week, APC sent an advisory memo to state boards of pharmacy raising concerns about adopting without careful consideration the new USP Chapter <797> restrictions on beyond-use dates and batch sizes.
House Energy & Commerce Committee Chair Cathy McMorris Rodgers (WA) and Senate Finance Committee Chair Mike Crapo (ID) have issued a joint request for information regarding the country's drug shortages...
The Nevada Legislature recently reversed a previous interpretation by the state's Board of Pharmacy that mandated out-of-state pharmacists to obtain a Nevada pharmacist license when dispensing or compounding prescriptions.